免疫系统
瓦博格效应
糖酵解
调节器
效应器
肿瘤微环境
乳酸脱氢酶A
癌症研究
细胞生物学
免疫疗法
表观遗传学
信号转导
组蛋白
医学
焊剂(冶金)
癌症免疫疗法
厌氧糖酵解
免疫检查点
新陈代谢
代谢途径
癌细胞
受体
乙酰化
基因表达调控
获得性免疫系统
生物
免疫
PD-L1
肿瘤进展
癌症
先天免疫系统
转录调控
生物化学
免疫学
作者
Zhenghui Tian,Kexin Zhang,Sufang Sheng,Chengxia Kan,Fang Han,Xiaodong Sun
标识
DOI:10.1097/coc.0000000000001276
摘要
Lactate, once viewed as a metabolic by-product of glycolysis, is now recognized as a central regulator in cancer biology. Accumulating evidence reveals that lactate actively participates in tumor progression by functioning as a metabolic fuel, signaling mediator, epigenetic modifier, and immune modulator. Tumor cells exhibit elevated glycolytic flux through the Warburg effect, producing large quantities of lactate through LDHA and exporting it through MCTs, which acidifies the tumor microenvironment and drives metabolic symbiosis, angiogenesis, and immune evasion. Lactate also stabilizes HIF-1α and activates the receptor GPR81, triggering signaling pathways that promote proliferation, invasion, and immune checkpoint expression. Epigenetically, lactate regulates histone acetylation and lactylation, modulating gene expression and supporting adaptive transcriptional programs. Immune suppression is reinforced through direct inhibition of effector T and NK cells and expansion of Tregs and MDSCs. Given its multifaceted role, lactate metabolism has emerged as a promising therapeutic target. Inhibitors of LDHA, MCT1/4, and GPR81 are under active development and show synergistic potential with immunotherapy and chemoradiotherapy. This review summarizes current advances in lactate biology and therapeutic strategies, highlighting the need for personalized approaches that consider tumor-specific lactate dependencies and signaling contexts.
科研通智能强力驱动
Strongly Powered by AbleSci AI